# Brenig Therapeutics

> Brenig Therapeutics is a neurology-focused biotechnology company building disease-modifying small-molecule therapies for Parkinson's disease and other neurodegenerative disorders. Founded in 2021 and backed by $65 million in Series A funding led by NEA, Brenig pairs AI- and machine-learning-driven discovery with structure-based design to engineer brain-penetrant molecules that hit the central nervous system while sparing the rest of the body. Its lead candidate, BT-267, is a selective LRRK2 inhibitor now in human trials, followed by BT-409, a brain-selective NLRP3 inflammasome inhibitor targeting neuroinflammation.

- **Founded:** 2021
- **Headquarters:** Dover, Delaware, United States
- **Founders:** OrbiMed (Co-founding investor), Torrey Pines Investments (Co-founding investor), BioGeneration Ventures (BGV) (Co-founding investor)
- **Team size:** ~4 employees (lean clinical-stage team)
- **Products:** BT-267 (LRRK2 inhibitor), BT-409 (NLRP3 inhibitor), AI/ML discovery platform
- **Notable:** Closed a $65M Series A led by NEA in July 2024., Advanced BT-267 from preclinical to first-in-human Phase 1 within roughly three years of founding., Reported a favorable safety and tolerability profile for BT-267 in Phase 1.

## Products & services

- **BT-267 (LRRK2 inhibitor)** — A selective, brain-penetrant small-molecule LRRK2 (leucine-rich repeat kinase 2) inhibitor with best-in-class potential, developed for both idiopathic Parkinson's and cases driven by LRRK2 mutations. Designed to maximize CNS exposure while minimizing peripheral activity. Advanced into first-in-human Phase 1 studies in late 2024, with a favorable safety and tolerability profile reported.
- **BT-409 (NLRP3 inhibitor)** — A highly selective, brain-selective small-molecule inhibitor of the NLRP3 inflammasome targeting neuroinflammation in Parkinson's and other neurodegenerative conditions. Entered first-in-human studies.
- **AI/ML discovery platform** — An artificial-intelligence and machine-learning-based drug discovery engine combined with structure-based design and decades of medicinal-chemistry expertise, used to engineer brain-penetrant small molecules with strong CSF-to-plasma ratios and clean safety profiles.

## Achievements

- Closed a $65M Series A led by NEA in July 2024.
- Advanced BT-267 from preclinical to first-in-human Phase 1 within roughly three years of founding.
- Reported a favorable safety and tolerability profile for BT-267 in Phase 1.
- Initiated a first-in-human study of BT-409, a brain-selective NLRP3 inhibitor.
- Selected for an oral presentation of BT-267 Phase 1 data at AD/PD 2026.

## Latest updates

- **2024-07** — Announced $65 million Series A financing led by NEA to advance its preclinical Parkinson's pipeline.
- **2024-11** — Initiated first-in-human Phase 1 study of LRRK2 inhibitor BT-267 in healthy volunteers.
- **2026-01** — Announced initiation of first-in-human study of BT-409, a brain-selective NLRP3 inhibitor, with an update on the BT-267 LRRK2 program.
- **2026-03** — Announced an oral presentation of BT-267 Phase 1 data at AD/PD 2026 and provided updates on the BT-409 program.

## Links

- Website: https://brenigther.com
- LinkedIn: http://www.linkedin.com/company/brenig-therapeutics
- Twitter/X: https://twitter.com/brenigther

---

Profile page: https://yespress.io/brenig-therapeutics
Published by YesPress — https://yespress.io
Last updated: 2026-06-15